TY - JOUR
T1 - Trans-Mediated, Cis-Inhibited Paradoxal Activity of Clostridium perfringens Enterotoxin (c-CPE) in Modulating Epithelial Permeability
AU - Sanchez, Julieta M.
AU - Favaro, Marianna T. P.
AU - López-Laguna, Hèctor
AU - Parladé, Eloi
AU - Di Somma, Angela
AU - Casanova Rigat, Isolda
AU - Unzueta, Ugutz
AU - Mangues, Ramon
AU - Vázquez Gómez, Esther
AU - Voltà-Durán, Eric
AU - Villaverde Corrales, Antonio
N1 - Publisher Copyright:
© 2025 American Chemical Society.
PY - 2025/3/11
Y1 - 2025/3/11
N2 - In the context of transdermal delivery, favoring the drug permeability of epithelia through convenient formulations would open new opportunities for local versus systemic drug delivery, envisaging higher patient comfort and an enhanced therapeutic effect. Ligands of tight junctions are interesting agents that enhance epithelial permeability by relaxing the protein complexes that form them. The C-terminal domain of Clostridium perfringens enterotoxin (c-CPE), which binds claudins, one of the tight junction (TJ) components, has been explored here as a functional domain in modular recombinant proteins, to evaluate its ability to self-promote its paracellular epithelial passage in a Caco-2 cell monolayer model. c-CPE-containing fusion proteins bind cells in the absence of internalization and cytotoxicity and support the passage, in trans, of other fusion proteins devoid of c-CPE. However, c-CPE-carrying proteins fail to cross the epithelia by themselves, probably because their affinity for TJs immobilizes them in the intercellular space. Therefore, while recombinant c-CPE versions have been here confirmed as convenient epithelial-permeabilizing agents, a paradoxical behavior has been observed where this effect is only successful when applied in trans, specifically on entities that lack c-CPE. Then, c-CPE itself inhibits the paracellular mobility of carrier molecules, not being suited as a self-driver (in c-CPE-drug complexes) for drug delivery through epithelia.
AB - In the context of transdermal delivery, favoring the drug permeability of epithelia through convenient formulations would open new opportunities for local versus systemic drug delivery, envisaging higher patient comfort and an enhanced therapeutic effect. Ligands of tight junctions are interesting agents that enhance epithelial permeability by relaxing the protein complexes that form them. The C-terminal domain of Clostridium perfringens enterotoxin (c-CPE), which binds claudins, one of the tight junction (TJ) components, has been explored here as a functional domain in modular recombinant proteins, to evaluate its ability to self-promote its paracellular epithelial passage in a Caco-2 cell monolayer model. c-CPE-containing fusion proteins bind cells in the absence of internalization and cytotoxicity and support the passage, in trans, of other fusion proteins devoid of c-CPE. However, c-CPE-carrying proteins fail to cross the epithelia by themselves, probably because their affinity for TJs immobilizes them in the intercellular space. Therefore, while recombinant c-CPE versions have been here confirmed as convenient epithelial-permeabilizing agents, a paradoxical behavior has been observed where this effect is only successful when applied in trans, specifically on entities that lack c-CPE. Then, c-CPE itself inhibits the paracellular mobility of carrier molecules, not being suited as a self-driver (in c-CPE-drug complexes) for drug delivery through epithelia.
KW - cCPE
KW - claudin
KW - drug delivery
KW - nanoparticles
KW - recombinant protein
KW - transactivity
KW - Caco-2 Cells
KW - Cell Membrane Permeability/drug effects
KW - Enterotoxins/metabolism
KW - Epithelial Cells/metabolism
KW - Clostridium perfringens/metabolism
KW - Humans
KW - Permeability/drug effects
KW - Claudins/metabolism
KW - Tight Junctions/metabolism
KW - Recombinant Fusion Proteins/metabolism
UR - https://www.scopus.com/pages/publications/86000593418
UR - https://www.mendeley.com/catalogue/609422b1-ea6f-3176-9843-dae227cd9801/
U2 - 10.1021/acs.molpharmaceut.4c01205
DO - 10.1021/acs.molpharmaceut.4c01205
M3 - Article
C2 - 40067325
SN - 1543-8384
VL - 22
SP - 1973
EP - 1982
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 4
ER -